MarketCap
Facebook
X
TelegramTranslate Bio, Inc. Market Cap | TBIO
As of November 08, 2026 Translate Bio, Inc. has a market cap of $ 2.81 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Translate Bio, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 1.23 B | 387 M | 153 M | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.23 B | 153 M | 589 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Adaptimmune Therapeutics plc
ADAP
|
2.05 B | - | -15.15 % | $ 60.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
122 M | - | - | $ 521 M |  USA |
 |
Codexis
CDXS
|
111 M | $ 1.09 | 6.37 % | $ 95 M | USA |
 |
MannKind Corporation
MNKD
|
990 M | $ 3.91 | 4.0 % | $ 1.2 B | USA |
 |
MediciNova
MNOV
|
69.2 M | $ 1.44 | -0.69 % | $ 70.7 M | USA |
 |
Axcella Health
AXLA
|
25 M | - | -16.42 % | $ 249 M | USA |
 |
Merck & Co.
MRK
|
311 B | $ 146.81 | -0.07 % | $ 367 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
1.73 B | - | - | $ 2.02 B | USA |
 |
Tyme Technologies
TYME
|
41.5 M | - | 8.07 % | $ 54 M | USA |
 |
Curis
CRIS
|
9.48 M | $ 0.88 | 3.67 % | $ 11.6 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
13 M | $ 34.99 | 3.77 % | $ 147 M | USA |
 |
Завод ДИОД
DIOD
|
661 M | - | - | - |  Russia |
 |
CorMedix
CRMD
|
456 K | $ 5.31 | 1.43 % | $ 383 K | USA |
 |
Novartis AG
NVS
|
316 B | $ 162.64 | 0.44 % | $ 315 B |  Schweiz |
 |
CRISPR Therapeutics AG
CRSP
|
4.39 B | $ 50.09 | 3.15 % | $ 4.5 B | Schweiz |
 |
PDS Biotechnology Corporation
PDSB
|
25 M | $ 1.22 | 4.27 % | $ 56.6 M | USA |
 |
Pfizer
PFE
|
155 B | $ 29.39 | -0.22 % | $ 167 B | USA |
 |
Pharming Group N.V.
PHAR
|
11.8 B | $ 12.32 | 0.16 % | $ 8.49 B |  Niderland |
 |
Orgenesis
ORGS
|
1.45 M | - | -33.86 % | $ 61.2 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
7.55 M | $ 53.74 | -3.26 % | $ 6.45 M | USA |
 |
Фармсинтез
LIFE
|
2 B | - | - | - | Russia |
 |
Prothena Corporation plc
PRTA
|
251 M | $ 7.93 | 0.51 % | $ 427 M | USA |
 |
Codiak BioSciences
CDAK
|
243 M | - | -55.98 % | $ 2.15 M | USA |
 |
DBV Technologies S.A.
DBVT
|
2.82 B | $ 10.54 | 7.55 % | $ 1.47 B |  France |
 |
Rocket Pharmaceuticals
RCKT
|
308 M | $ 2.38 | -2.05 % | $ 264 M | USA |
 |
Regeneron Pharmaceuticals
REGN
|
81.3 B | $ 904.69 | 0.2 % | $ 94.6 B | USA |
 |
Replimune Group
REPL
|
1.04 B | $ 21.67 | 8.24 % | $ 2.01 B | USA |
 |
DiaMedica Therapeutics
DMAC
|
312 M | $ 9.47 | 4.76 % | $ 445 M | USA |
 |
Royalty Pharma plc
RPRX
|
18.9 B | $ 67.31 | -0.39 % | $ 28.9 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
160 M | - | - | $ 169 M | USA |
 |
Rhythm Pharmaceuticals
RYTM
|
6.34 B | $ 111.51 | 6.18 % | $ 7.25 B | USA |
 |
Puma Biotechnology
PBYI
|
378 M | $ 8.28 | -15.25 % | $ 414 M | USA |
 |
SIGA Technologies
SIGA
|
404 M | $ 3.12 | 4.55 % | $ 223 M | USA |
 |
Sage Therapeutics
SAGE
|
434 M | - | - | $ 527 M | USA |
 |
Taro Pharmaceutical Industries Ltd.
TARO
|
1.36 B | - | - | $ 1.62 B |  Israel |
 |
Sol-Gel Technologies Ltd.
SLGL
|
203 M | $ 61.62 | -2.21 % | $ 172 M | Israel |
 |
SELLAS Life Sciences Group
SLS
|
567 M | $ 8.41 | 6.73 % | $ 917 M | USA |
 |
Summit Therapeutics
SMMT
|
12 B | $ 16.34 | 15.15 % | $ 12.2 B | Britain |
 |
Cabaletta Bio
CABA
|
283 M | $ 1.3 | 1.17 % | $ 131 M | USA |
 |
Syndax Pharmaceuticals
SNDX
|
1.73 B | $ 9.53 | 1.39 % | $ 826 M | USA |
 |
Sanofi
SNY
|
59.3 B | $ 47.06 | 0.32 % | $ 57.4 B | France |
 |
Forma Therapeutics Holdings
FMTX
|
467 M | - | - | $ 958 M | USA |
 |
Blueprint Medicines Corporation
BPMC
|
5.96 B | - | - | $ 8.14 B | USA |
 |
Horizon Therapeutics Public Limited Company
HZNP
|
25.2 B | - | - | $ 26.6 B |  Irlanda |
 |
Sarepta Therapeutics
SRPT
|
1.64 B | $ 17.8 | 0.68 % | $ 1.78 B | USA |
 |
Paratek Pharmaceuticals
PRTK
|
81 M | - | - | $ 121 M | USA |
 |
China SXT Pharmaceuticals
SXTC
|
1.14 M | $ 2.84 | -3.07 % | $ 1.93 M |  China |
 |
Takeda Pharmaceutical Company Limited
TAK
|
23.8 B | $ 21.02 | -0.92 % | $ 33.2 B |  Japan |
 |
Tarsus Pharmaceuticals
TARS
|
2.92 B | $ 68.11 | 0.87 % | $ 2.85 B | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
427 M | - | -14.27 % | $ 1.7 M |  Singapore |